Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

h more than 371 million people worldwide living with the condition today.

About Sanofi Diabetes Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

About SanofiSanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

References

  1. Tillner J et al. Euglycemic Clamp Profile of New Insulin Glargine U300 Formulation in Patients With Type 1 Diabetes (T1DM) is Different From Glargine U100.73rd Scientific Sessions of the ADA, abstract no. 920-P
  2. Dahmen R et al New Insulin Glargine U300 Formulation Evens and Prolongs Steady State PK and PD Profiles During Euglycemic Clamp in Patients With Type 1 Diabetes (T1DM)". 73rd Scientific Sessions of the ADA, abstract no. 113-OR

Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to futu
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0324750/Virtual-Pharma.html ... in the pharmaceutical market has slowed – almost to a ... cutting costs in a faltering world economy. ...
... NEW YORK, Nov. 3, 2010 Pfizer Inc. (NYSE: ... public to view and listen to a webcast of ... Primary Care, at the 2010 Annual Credit Suisse Healthcare ... Mountain Standard Time. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Virtual Pharma 2Reportlinker Adds Virtual Pharma 3Reportlinker Adds Virtual Pharma 4Reportlinker Adds Virtual Pharma 5Reportlinker Adds Virtual Pharma 6
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... boosted 50-fold to 100,000-fold, study finds , , THURSDAY, Dec. 13 ... an international team reports that tiny fibers commonly found in ... its damage. , According to a study in the Dec. ... virus and then ferry it to target cells, increasing its ...
... males and females in order to alleviate back pressure ... research spearheaded at The University of Texas at Austin. ... time in the Dec. 13 issue of Nature. , ... two million years ago, in the early human ancestor ...
... and safety grounds , , THURSDAY, Dec. 13 (HealthDay ... U.S. Food and Drug Administration advisory panel has been asked ... over the counter. , But with groups such as the ... against it, experts think Merck,s proposal is likely to be ...
... to see, the mammalian eye also detects light for a ... the timing of the sleep/wake cycle, which is synchronized by ... hypothalamus. , In a study published online on December ... humans whose non-visual responses to light remain intact, suggesting that ...
... of counseling can reverse seasonal ... stress-related infertility, ... medical specialists are encouraged by new research,pointing toward an age-old ... year-end holiday blues, which doctors say can,actually have physical effects ...
... an advanced,electronic nebulizer, was optimized and used to ... trial. Results of the Phase I trial were,announced ... the Lungs meeting held,in Edinburgh, U.K. ALN-RSV01 is ... respiratory syncytial virus (RSV) infection, the leading,cause of ...
Cached Medicine News:Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2Health News:FDA Panel Considering Over-the-Counter Statin 2Health News:FDA Panel Considering Over-the-Counter Statin 3Health News:FDA Panel Considering Over-the-Counter Statin 4Health News:FDA Panel Considering Over-the-Counter Statin 5Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 3Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 2Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 3Health News:PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study 2
Rhoton #12 straight point needle semisharp, titanium....
Micro 2000, micro scissors micro 2000 supercut....
Micro 2000 suture forceps light-weight instruments with blue-colored anodized round handles, extremely light weight, well balanced, easy to handle, fatigueless working, easy to maintain, corrosion-re...
Mini blades....
Medicine Products: